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In this work alginate and alginate-chitosan beads containing celecoxib solubilized into a self-emulsifying phase were developed
in order to obtain a drug delivery system for oral administration, able to delay the drug release in acidic environment and to
promote it in the intestinal compartment. The rationale of this work was linked to the desire to improve celecoxib therapeutic
effectiveness reducing its gastric adverse effects and to favor its use in the prophylaxis of colon cancer and as adjuvant in the therapy
of familial polyposis. The systems were prepared by ionotropic gelation using needles with different diameters (400 and 600 𝜇m).
Morphology, particle size, swelling behavior, and in vitro drug release performance of the beads in aqueous media with different
pH were investigated. The experimental results demonstrated that the presence of chitosan in the formulation caused an increase
of the mechanical resistance of the bead structure and, as a consequence, a limitation of the bead swelling ability and a decrease of
the drug release rate at neutral pH. Alginate-chitosan beads could be a good tool to guarantee a celecoxib colon delivery.
1. Introduction
Drug delivery systems containing biodegradable natural
polymers are the object of more and more research studies
considering the advantages that these materials can offer [1].
Among them, those containing alginate and chitosan have
been widely exploited in pharmaceutical field [2–4].
Alginate is a water soluble natural biopolymer extracted
from brown algae and composed of alternating blocks of
1-4 𝛼-L-guluronic and 𝛽-D-mannuronic acid residues [5].
This polymer forms hydrogels in presence of divalent cations
like Ca2+, Ba2+, Sr2+, and Zn2+ [6, 7] and this characteristic
allows preparing drug loaded beads [8]. The mechanism of
this gelation process involves guluronic residues with the
specific chelation of Ca2+ forming the so-called “egg-box”
structure [9]. Many researchers focused their attention on
the development of calcium alginate beads as controlled
drug delivery systems for the oral administration of drug
molecules and proteins [10–12].
Chitosan is a biocompatible, biodegradable, nontoxic,
linear polysaccharide composed of D-glucosamine and N-
acetyl-D-glucosamine units linked by 𝛽-(1-4) glycosidic
linkages [13]. Chitosan can be derived by partial deacetylation
of chitin from crustacean shells and it is widely used for cell
culture, drug delivery, and food additives [14–16].
Cross-linking of alginate and chitosan in a hydrogel is
used to provide materials useful for medical and pharma-
ceutical applications; the obtained systems are characterized
by enhanced stability compared to those obtained with a
single polymer [17, 18]. In controlled drug delivery alginate-
chitosan polyelectrolyte complex has receivedmuch attention
in recent years [12, 19–22]. The two polymers form the
polyelectrolyte complex via the ionic interaction between
the carboxyl residues of alginate and the amino residues of
chitosan. The alginate-chitosan beads can be produced by
different methods: the two-step procedure and the one-step
procedure [23]. In the first one, calcium alginate gel beads
are produced by dropping a solution of alginate into a gelling
bath containing calcium ions. The resulting beads are then
transferred into a chitosan solution to form the membrane
on their surface. The one-step procedure requires that the
droplets of alginate solution fall into an aqueous solution
containing both the gelling agent for alginate (e.g., calcium
ions) and chitosan [24].The choice of the productionmethod
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Table 1: Composition of calcium alginate and calcium alginate-chitosan beads.
Formulation Sodium alginate (% w/w) Self-emulsifying phase (% w/w) Gelling bath Needle diameter (𝜇m)
Cal 600 1.5
Celecoxib 27.4
CaCl
2
100mM 600Labrasol 68.5
TPGS 4.1
Cal 400 1.5
Celecoxib 27.4
CaCl
2
100mM 400Labrasol 68.5
TPGS 4.1
CAlCh 600 1.5
Celecoxib 27.4
CaCl
2
100mM + 0.2% chitosan 600Labrasol 68.5
TPGS 4.1
CAlCh 400 1.5
Celecoxib 27.4
CaCl
2
100mM + 0.2% chitosan 400Labrasol 68.5
TPGS 4.1
is responsible for the properties of the beads because of
the amount of bound chitosan in the resulting product. At
the same time, the characteristics of the beads are affected
by the molecular weight of the selected polymers and/or
by the percentages of the various residues in the polymeric
molecules [25, 26].
Celecoxib, a fluorinated benzenesulfonamide derivative,
is a nonsteroidal anti-inflammatory drug (NSAID) with a
highly selective cyclooxygenase-2 (COX-2) inhibitory action.
It possesses anti-inflammatory, analgesic, and antipyretic
activities due to the inhibition of prostaglandin synthesis
catalyzed by COX-2. Recently, this drug was frequently
investigated for its anticancer activity using in vitro and
in vivo models [27–30]. Preclinical studies on celecoxib
reported prominent anticancer activity against head and neck
squamous cell carcinoma, colon cancer, breast cancer, and
lung cancer [27, 28].
In this work alginate and alginate-chitosan beads con-
taining celecoxib solubilized into a self-emulsifying phase
were developed in order to obtain a drug delivery system for
oral administration, able to delay the drug release in acidic
environment and to promote it in the intestinal compart-
ment. The rationale of this work was linked to the desire
to improve celecoxib therapeutic effectiveness reducing its
gastric adverse effects and to favor its use in the prophylaxis
of colon cancer and as adjuvant in the therapy of familial
polyposis [31–33]. The aim of the current study was the
evaluation and the comparison of the properties of celecoxib
loaded calcium alginate and calcium alginate-chitosan beads.
Morphology, particle size, swelling behavior, and in vitro drug
release performance of beads in aqueousmedia with different
pH were investigated.
2. Materials and Methods
2.1. Materials. Celecoxib was obtained from Chemos GmbH
(Regenstauf, Germany). Anhydrous calcium chloride and
sodium alginate (molecular weight 120000–190000 g/mol;
1.56 mannuronic-guluronic residues ratio) were purchased
from Sigma Aldrich (Milan, Italy), while low molecular
weight chitosan was from Fluka (Milan, Italy). Labrasol
(caprylocaproyl macrogol-8 glycerides) was a gift of Gatte-
fosse` (Milan, Italy); TPGS (D-𝛼-tocopheryl polyethylengly-
col 1000 succinate) was kindly donated by Isochem (Gen-
nevillers, France). All other chemicals were of analytical
grade.
2.2. Preparation of Calcium Alginate Beads. Calcium alginate
beads were prepared by gelation method using calcium
ions as cross-linking agent. In detail, a 1.5% (w/w) sodium
alginate aqueous solution was mixed with a drug loaded self-
emulsifying phase in 4 : 1 ratio and added drop by drop to
a 100mMCaCl
2
solution [34]. The self-emulsifying phase
was prepared mixing weighed amounts of Labrasol and
TPGS at 50∘C and dissolving celecoxib in the excipient
solution. The emulsion (sodium alginate solution and self-
emulsifying phase) was manually extruded in the hardening
bath through needles with 400 or 600𝜇m inner diameter,
under constant gentle stirring, at room temperature. After
15 minutes, the beads were collected, washed with deionised
water to eliminate the excess of calcium ions and then dried at
40∘C overnight. The composition of prepared formulations,
coded CAl 600 and CAl 400, was listed in Table 1.
2.3. Preparation of Calcium Alginate-Chitosan Beads. Cal-
cium alginate-chitosan beads (identified as CAlCh 600 and
CAlCh 400) were prepared according to the one stepmethod.
The procedure was identical to that adopted in the case of
alginate beads with the exception that the hardening bath
was a 0.2% (w/w) chitosan solution in diluted acetic acid
(1%) containing CaCl
2
at a concentration of 100mM. The
composition of the chitosan formulations was reported in
Table 1.
2.4. Morphological and Particle Size Analysis. The morphol-
ogy of the wet and dried beads and the particle size of the
dried beads were analysed using a Motic SMZ168 stereomi-
croscope and an image analysis software (Motic Image Plus
2.0). For each formulation, the particle size was calculated as
the average value of the size of 20 dried particles.
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2.5. Drug Content. Sixmilligrams of drug loaded dried beads
was solubilized in phosphate buffer solution (100mL) at
pH 6.8 added of 0.75% (w/v) sodium laurylsulphate at 70∘C
under stirring for two hours. After cooling, the obtained
solutions were filtrated and analysed spectrophotometrically
at 255 nm; the results are the average of at least three
determinations.
2.6. Swelling Study. Swelling studies were carried out at 37∘C
on dried beads put into three aqueous media characterized
by different pH: hydrochloric acid at pH 1.0 and phosphate
buffer at pH 6.8 and pH 7.4.
Accurately weighed amounts of calcium alginate and
calcium alginate-chitosan dried beads were put in glass vials
containing 5mL of each fluid. After fixed time intervals (5,
15, 30, 60, and 120 minutes), the samples were recovered,
gently wiped with paper, and weighed again. The dynamic
weight change of the beads with respect to time, defined
as swelling degree (Sw), was calculated according to the
following equation:
Sw% =
𝑊
𝑡
−𝑊
0
𝑊
0
× 100, (1)
where𝑊
𝑡
is the weight of the beads in the swollen state at time
𝑡 and𝑊
0
is the initial weight of the dried beads [35].
2.7. Celecoxib Release Study. The in vitro release studies were
performed in hydrochloric acid at pH 1.0 and in phosphate
buffer at pH 6.8 and at pH 7.4 added of 0.75% sodium
laurylsulphate to guarantee the maintenance of the sink
conditions.The studies were carried out by placing accurately
weighed amounts of each formulation, equivalent to 8mg
of celecoxib, in 500mL of the selected fluid at 37∘C under
a rotation rate of 100 rpm (apparatus 2, paddle). Filtered
samples were withdrawn at specific time intervals without
replacement and analysed for celecoxib content using an
UV spectrophotometer at 255 nm when the fluid was HCl
and phosphate buffer at pH 6.8 or at 256 nm in the case of
phosphate buffer at pH 7.4. Each experiment was done in
triplicate.
The drug release performances of calcium alginate and
calcium alginate-chitosan beads were compared using the
dissolution parameters t10%, t50%, and t90% which indicate
the time points at which 10%, 50%, and 90% of the drug
were released [36] and the f2 similarity parameter [37]. For
curves to be considered similar f2 values should be close to
100, and f2 values greater than 50 (50–100) ensure sameness
or equivalence of the two curves.
2.8. Statistical Analysis. The results were statistically analysed
to test significant differences by Student’s t-test, at 95%
confidence interval; 𝑝 values less than 0.05 were considered
statistically significant.
3. Results and Discussion
Alginate and alginate-chitosan beads were obtained by
ionotropic gelationmethod dropping an emulsion, composed
of alginate aqueous solution and the drug loading self-
emulsifying phase, through 23G (600𝜇m) or 27G (400 𝜇m)
needles, in a calcium chloride or in a calcium chloride-
chitosan gelling bath. The excipients selected for the self-
emulsifying phase were Labrasol, a liquid component with
self-emulsifying and solubility enhancer properties, andD-𝛼-
tocopheryl polyethylenglycol 1000 succinate as coemulsifying
and absorption enhancer agent (Table 1). The composition of
the self-emulsifying phase was the same used in a previous
work [34].
Stereomicroscopic images of wet and dry alginate and
alginate-chitosan beads are reported in Figures 1 and 2.
Immediately after the preparation CAl 600 beads (Fig-
ure 1(a)) show regular shape and homogeneous dimensions;
they are white and opaque with a smooth, glossy, and
homogeneous surface.
The drying process does not change the shape of beads
but leads to the reduction of their dimensions and modifies
the characteristics of their surface, which is irregular and
wrinkled (Figure 1(b)). The loss of water induces a decrease
of the distance between the polymeric chains and a variation
of the structure of the beads, which is not compact and
continuous but composed of small micronuclei adhering
to each other. The fully swollen CAlCh 600 particles are
slightly yellow and quite regular in shape and show a smooth
surface (Figure 1(c)). In this case, the drying process affects
the spherical shape of the beads (Figure 1(d)); they become
ellipsoidal; their dimension decreases and their surface is very
rough.Moreover, after drying a partial surface agglomeration
of the beads is observed: it is attributable to the adhesive prop-
erties of chitosan [38]. In the case of beads prepared using
a 400 𝜇m needle (Figures 2(a)–2(c)), the images recorded
immediately after the preparation give evidence that for both
the formulations (with or without chitosan) particles are not
homogeneous in diameters even if they are regular in shape.
CAl 400 and CAlCh 400 dry beads (Figure 2(b)) have a
surface characterized by asperity and concavity; moreover, in
the case of alginate-chitosan formulation the particle shape
is completely irregular and the presence of solid bridges of
chitosan is well evident which bind the beads impeding their
separation.
Average size of celecoxib loaded beads is between 715
and 896 𝜇m (Table 2). The diameter of the beads was
significantly affected by the diameter of the needle used
during preparation (𝑝 < 0.05). The addition of chitosan to
alginate beads changes significantly their dimensions only
when the 400𝜇m needle was used (𝑝 < 0.05). Moreover, as
indicated by the high values of the standard deviation, using
the 400 𝜇m needle the final product is a family of particles
inhomogeneous in dimensions.
All the formulations contain high amount of drug
(Table 2) homogeneously distributed in the excipient matrix
and the differences among their drug content were not
significant except for CAlCh 400 slightly lower than the
others (𝑝 < 0.001). The percentage of celecoxib in the beads
exceeds the theoretical value and this is due to the loss of
Labrasol during the curing time [34], justifiable considering
the high affinity between this excipient and water which
drives it out of the beads into the gelling bath.
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CAl 600
(a)
CAlCh 600
(b)
(c) (d)
Figure 1: Stereomicroscopic images of wet (a-b) (2xmagnification) and dry (c-d) (3xmagnification) beads obtained using a needle of 600 𝜇m
in diameter.
CAl 400
(a)
CAlCh 400
(b)
(c) (d)
Figure 2: Stereomicroscopic images of wet (a-b) (2xmagnification) and dry (c-d) (3xmagnification) beads obtained using a needle of 400 𝜇m
diameter.
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Table 2: Average diameter and celecoxib content of the dry beads.
Diameter (𝜇m) Drug content (%)
CAl 600 896 ± 64.24 42.10 ± 1.30
CAl 400 715 ± 80.96 43.63 ± 0.77
CAlCh 600 881 ± 66.87 40.94 ± 1.37
CAlCh 400 795 ± 103.70 39.78 ± 0.66
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Figure 3: Swelling degree in hydrochloric acid at pH 1.0.
A peculiar property of alginate or alginate-chitosan
microparticulate systems in the dry form is their ability,
after contact with an aqueous fluid, to rehydrate, take up the
fluid, and undergo a swelling process, mainly associated with
the hydration of the hydrophilic groups of polymers. When
the fluid is water, it penetrates into the particles filling the
pores among the polymeric chains and causing an impor-
tant swelling of the system, without erosion/disintegration.
Selecting fluids with different pH, the swelling behavior of
the beads could change. For this reason, the swelling ability
of calcium alginate and of calcium alginate-chitosan beads
has been evaluated in HCl at pH 1.0 and in phosphate buffer
solutions at pH 6.8 and 7.4 (Figures 3–5).
In acidic environment (Figure 3), there are no differences
in the swelling ability of the four formulations; at this pH, the
maximum swelling degree is not over 60%. The alginate and
alginate-chitosan beads absorb part of the fluid; their weight
initially increases and then remains constant. At this pH, for
the alginate systems (CAl 600 and CAl 400), the carboxylate
groups of the polymer localized on the surface of particles are
protonated and a layer of alginic acid forms. The insolubility
of alginic acid in this fluid and the formation of hydrogen
bonds, responsible for an increase of the structure stability,
impede the penetration of additional fluid into the deeper
layers of particles, limiting their swelling. The same swelling
behavior is observed for CAlCh 600 and CAlCh 400 systems.
Even if, in acidic environment, chitosan is highly soluble
and charged for the conversion of its amine units into NH3+
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Figure 4: Swelling degree in phosphate buffer at pH 6.8.
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Figure 5: Swelling degree in phosphate buffer at pH 7.4.
soluble form, the interaction of amino groups and protonated
carboxylic groups is not strong enough to promote swelling.
Thus, the limited total swelling behavior is dominated by
calcium alginate structure.
Figures 4 and 5 show that the formulations exhibit
high swelling ability at pH 6.8 and pH 7.4. For CAl 600
formulation, the weight of particles grows rapidly, reaches a
peak after 30 minutes, and then decreases abruptly because
of the erosion/disintegration of the system. This behavior
can be due to ion exchange reaction between Na+ (present
in the phosphate buffer) and Ca2+ linked to carboxylic
groups of alginate. Monovalent ions replace bivalent ones
causing the breakup of the “egg-box” structure and the
increase of the distance between the polymeric chains and
favoring the fluid absorption and the swelling of the systems.
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Figure 6: Celecoxib release profiles in hydrochloric acid at pH 1.0.
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Figure 7: Celecoxib release profiles in phosphate buffer at pH 6.8.
This process goes on until the osmotic pressure into the
beads balances the strength of the cross-linking bonds and
physical entanglements, which preserve the structure of the
beads. Thus, particles start to disintegrate and their weight
diminishes.
The results obtained from the swelling study evidence
that CAlCh 600 and CAlCh 400 beads are characterized by a
more resistant structure compared to CAl 600 and CAl 400,
probably attributable to the interactions between alginate and
chitosan chains. The maximum swelling degree of chitosan
beads is lower than that of the alginate; alginate-chitosan
systems are able to reach a swelling equilibrium in about 30
minutes and to maintain their weight at a constant level until
the end of the test. Probably the interactions between the two
polymers are responsible for the formation of particles with
a considerable mechanical resistance, which limits the fluid
uptake and the structure disintegration. Finally, comparing
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Figure 8: Celecoxib release profiles in phosphate buffer at pH 7.4.
the swelling behavior of CAl 400 versus CAl 600 and CAlCh
400 versus CAlCh 600 beads (same composition, different
diameter of the needle used in the preparation process), it is
possible to note that in phosphate buffers CAl 400 andCAlCh
400 reached a swelling maximum peak higher than that of
CAl 600 and CAlCh 600, respectively.
The drug release profiles obtained from the different
formulations at pH of 1.0, 6.8, and 7.4 are shown in Figures
6–8. The in vitro celecoxib release is affected by the pH of
the selected fluid: the percentage of drug released in acidic
medium in two hours is quite low and varies between 12.70%
and 24.53% (Figure 6). The delay of celecoxib release can be
ascribed to the reduced swelling ability of the systems in this
fluid; neither the composition of the beads nor their diameter
affects the drug release performance (f2 parameter values
always over 50). At pH 1.0, the release process is governed
only by the diffusion of the drug. This result allows satisfying
the first object of this research work that is to minimize drug
delivery in acidic environment to promote and favor this
process at intestinal level.
In phosphate buffer at pH 6.8, the formulations are
characterized by a drug release behavior affected by their
composition and not significantly by their dimensions (Fig-
ure 7). In this fluid, the systems initially swell and then
erode/disintegrate and, consequently, the drug release pro-
cess is driven at first by diffusion and then by the polymeric
relaxation. Alginate beads (CAl 600 and CAl 400) are able
to complete the celecoxib release in about eight hours; on
the contrary no more than 75% of the drug loaded in
alginate-chitosan beads passes in solution after the same time.
The comparison of the results from alginate and alginate-
chitosan microparticle formulations reveals that the profiles
are not similar having f2 values lower than 50. A possible
explanation for such a behavior is the electrostatic interaction
between carboxyl groups of the alginate and the amino group
of chitosan that improves the mechanical resistance of the
polymeric network reducing its swelling and erosion at pH
6.8.
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Table 3: Time (min) necessary to release 10, 50, and 90% of the
loaded drug.
CAl 600 CAl 400 CAlCh 600 CAlCh 400
HCl
𝑡10% 24 12 31 85
𝑡50% — — — —
𝑡90% — — — —
pH 6.8
𝑡10% 16 19 10 30
𝑡50% 130 110 261 310
𝑡90% 290 220 >8 h >8 h
pH 7.4
𝑡10% 16 25 28 35
𝑡50% 229 187 423 >8 h
𝑡90% >8 h 444 >8 h >8 h
Surprisingly, the celecoxib release rate slows downmainly
for CAlCh 400 formulation even if this formulation is
characterized by the lowest particle size. Probably the small
diameter and the high surface area of these particles lead to
the formation of a thicker chitosan layer around the beads,
which opposes a great resistance to the fluid uptake and, as a
consequence, to the drug release.
Also at pH 7.4 the differences in the drug release per-
formances can be attributed to the formulation composition
rather than to the particle dimensions (Figure 8). All the
formulations showed an almost constant drug release rate.
There are no differences between CAl 600 and CAl 400 and
between CAlCh 600 and CAlCh 400 release curves; when
chitosan is in the beads, the drug release rate decreases.
The same conclusions are shown by the analysis of the
results of the drug release through the dissolution parameters
(t10%, t50%, and t90%) (Table 3). The differences in the
release behavior of the beads are detected also through the
dissolution parameters t10%, t50%, and t90% and are well
evident for the time necessary to release 50 and 90% of
the loaded drug. In phosphate buffer solutions, alginate-
chitosan beads require longer times to deliver 50 and 90% of
celecoxib compared to alginate beads. Probably the presence
of the alginate-chitosan complex provokes a growth of the
structural wrinkles, irregularity and complexity of the bead
structure, which make the drug liberation difficult.
4. Conclusions
The investigated celecoxib loaded alginate and alginate-
chitosan beads minimize the drug release in acidic environ-
ment favoring this process at intestinal pH (6.8 and 7.4).
The experimental results demonstrate that the presence of
chitosan in the formulation is responsible for an increase of
the resistance of the bead structure and, as a consequence, for
a limitation of the bead swelling ability and for a decrease of
the drug release rate at neutral pH. Alginate-chitosan beads
could be a valuable vehicle of celecoxib for dosage forms
useful as adjuvant therapy in patients with familial polyposis
and precancerous disease of colon.
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